Lubomir Sokol
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lubomir Sokol as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:46 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT06235281 · Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)H. Lee Moffitt Cancer Center and Research Institute · suspended · Mycosis Fungoides · principal investigator
- Early Ph1NCT05316116 · Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)H. Lee Moffitt Cancer Center and Research Institute · terminated · Large Granular Lymphocyte Leukemia · principal investigator
- N/ANCT01841021 · Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30H. Lee Moffitt Cancer Center and Research Institute · terminated · Peripheral T-Cell Lymphoma · principal investigator
- N/ANCT01671813 · Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyH. Lee Moffitt Cancer Center and Research Institute · withdrawn · Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:46 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.J Clin Oncol · 2012566 citationsRCR 14.1
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.Lancet Oncol · 2018563 citationsRCR 19.4
- 242 citationsRCR 10.3
- Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.J Clin Oncol · 2020210 citationsRCR 9.0
- Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.J Clin Oncol · 2010190 citationsRCR 4.7
- 190 citationsRCR 5.9
- Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.J Hematol Oncol · 2014184 citationsRCR 4.6
- A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.Clin Cancer Res · 2013181 citationsRCR 5.1
- 167 citationsRCR 9.0
- Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.Blood · 2006112 citationsRCR 2.2